US · LIXT
Lixte Biotechnology Holdings, Inc.
- Sector
- Healthcare · Biotechnology
- Headquarters
- Pasadena, CA 91101
- Website
- lixte.com
Price · as of 2024-12-31
$3.37
Market cap 13.15M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | — | — |
| Intrinsic Value(DCF) | — | — |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | $45.00 | ||||
| 2011 | $52.80 | ||||
| 2012 | $21.00 | ||||
| 2013 | $9.00 | ||||
| 2014 | $15.00 | ||||
| 2015 | $14.40 | ||||
| 2016 | $12.00 | $407.88 | |||
| 2017 | $7.80 | ||||
| 2018 | $49.80 | ||||
| 2019 | $53.40 | ||||
| 2020 | $43.70 | ||||
| 2021 | $11.40 | ||||
| 2022 | $7.20 | ||||
| 2023 | $2.43 | ||||
| 2024 | $1.20 |
AI valuation
Our deep-learning model estimates Lixte Biotechnology Holdings, Inc.'s (LIXT) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- —
- Current price
- $3.37
- AI upside
- —
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
—
— upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| LIXT | Lixte Biotechnology Holdi… | $3.37 | 13.15M | — | — | — | — | -0.75 | 3.26 | — | -0.47 | — | 3.26 | 0.00% | — | — | -148.73% | 1699.47% | -131.50% | 0.00 | — | 3.26 | 3.26 | 0.29 | -4023.00% | — | -2629.00% | -117.26% | -9.94 | 1505.28% | 0.00% | 0.00% | 0.00% | -0.46 | -0.52 | — | -68.09 |
| ALLR | Allarity Therapeutics, In… | $0.97 | 15.6M | — | — | — | — | -0.07 | 0.14 | — | 0.68 | — | 0.14 | 0.00% | — | — | -541.17% | 671.53% | -142.07% | 0.11 | -41.72 | 2.06 | 2.01 | 0.75 | -9974.00% | — | 3849.00% | -1036.16% | -1.60 | 441.86% | 0.00% | 0.00% | 1339.49% | 0.60 | 0.93 | — | -10.62 |
| BCTX | BriaCell Therapeutics Cor… | $3.82 | 7.2M | — | — | — | — | -0.64 | 0.95 | — | 0.03 | -1.44 | 0.96 | 0.00% | — | — | -343.04% | 1683.01% | -192.49% | 0.00 | -735.71 | 5.01 | 4.63 | 0.39 | 4450.00% | — | 1632.00% | -167.26% | -7.14 | 1742.76% | 0.00% | 0.00% | 56.64% | 0.03 | 0.03 | — | -8.16 |
| CASI | CASI Pharmaceuticals, Inc… | $0.21 | 3.21M | +5,727% | +324% | — | +8,512% | -0.86 | 18.23 | 1.18 | -1.14 | -3.22 | 20.92 | 39.06% | -138.84% | -137.57% | -301.80% | -351.62% | -60.89% | 11.96 | -45.49 | 1.09 | 0.86 | -0.25 | 2673.00% | -1577.00% | 3267.00% | -87.31% | -0.80 | -261.48% | 2.13% | -1.80% | 2.13% | -1.00 | -1.35 | 1.39 | -19.70 |
| CING | Cingulate Inc. | $6.27 | 35.15M | — | — | — | — | -0.95 | 1.97 | — | -0.51 | — | 1.97 | 0.00% | — | — | -5305.02% | 1019.77% | -169.38% | 0.68 | — | 2.55 | 2.46 | 0.48 | -9673.00% | — | 2231.00% | -126.84% | -3.71 | 1216.50% | 0.00% | 0.00% | 71.84% | -0.49 | -0.41 | — | -11.88 |
| CLSD | Clearside Biomedical, Inc… | $0.41 | 2.15M | +4,171% | +1,944,915% | — | +116,036% | -1.99 | -1.76 | 41.15 | -4.15 | — | -1.76 | 91.05% | -1735.70% | -2064.42% | 125.45% | 701.36% | -116.16% | -1.35 | -2.95 | 4.44 | 4.28 | 0.79 | -1132.00% | -7977.00% | 2894.00% | -37.50% | -5.15 | 623.48% | 0.00% | 0.00% | 48.77% | -3.49 | -3.93 | 60.65 | -22.09 |
| ENTO | Entero Therapeutics, Inc. | $2.85 | 13.58M | — | — | — | — | -0.43 | 0.13 | — | -491.36 | — | 0.14 | 0.00% | — | — | -58.82% | -0.05% | -39.13% | 0.00 | — | 3.03 | 0.01 | 1.47 | -8880.00% | — | -2842.00% | -119.84% | -0.33 | -31.51% | 0.00% | 0.00% | 0.00% | -490.90 | -0.83 | — | -2.37 |
| HOTH | Hoth Therapeutics, Inc. | $1.01 | 13.39M | — | — | — | — | -0.85 | 1.01 | — | -2.17 | — | 1.01 | 0.00% | — | — | -99.75% | -9559.27% | -91.21% | 0.00 | — | 9.20 | 8.52 | -258.29 | -4435.00% | — | -1739.00% | -100.42% | -8.40 | -8119.72% | 0.00% | 0.00% | 0.00% | 0.01 | 0.01 | — | -8.42 |
| LEXX | Lexaria Bioscience Corp. | $0.70 | 13.51M | +3,989% | -40% | — | — | -1.57 | 6.26 | 26.52 | -1.43 | -3.89 | 6.98 | 83.20% | -1647.97% | -1686.00% | -216.06% | -846.18% | -182.65% | 0.04 | — | 2.32 | 1.56 | 0.14 | 4043.00% | 5205.00% | 10942.00% | -55.96% | -7.00 | -761.93% | 0.00% | 0.00% | 0.00% | -1.45 | -1.61 | 23.88 | -22.60 |
| PULM | Pulmatrix, Inc. | $2.99 | 10.92M | +6,325% | — | — | — | -1.34 | 1.81 | — | -0.55 | — | 1.81 | 0.00% | — | — | -80.93% | 1213.38% | -73.31% | 0.00 | — | 12.55 | 12.43 | 0.79 | -4618.00% | -10000.00% | -5112.00% | -78.71% | -16.51 | 1275.35% | 0.00% | 0.00% | 0.00% | -0.54 | -0.52 | — | -92.69 |
About Lixte Biotechnology Holdings, Inc.
Lixte Biotechnology Holdings, Inc. operates as a drug discovery company that uses biomarker technology to identify enzyme targets related with serious common diseases and designs novel compounds to attack those targets. The company primarily focuses on inhibitors of protein phosphatases that are used alone and in combination with cytotoxic agents and/or x-ray and immune checkpoint blockers; and encompasses two major categories of compounds at various stages of pre-clinical and clinical development. It develops two series of pharmacologically active drugs, which include the LB-100 series that consists of novel structures for the treatment of cancers, and vascular and metabolic diseases; and LB-200 series to treat chronic hereditary diseases, such as Gaucher's disease, as well as cancer and neurodegenerative diseases. Lixte Biotechnology Holdings, Inc. has a clinical trial research agreement with the Moffitt Cancer Center and Research Institute Hospital Inc.; collaboration agreement for an investigator-initiated clinical trial with the Spanish Sarcoma Group, as well as Netherlands Cancer Institute and Oncode Institute. The company was founded in 2005 and is based in Pasadena, California.
- CEO
- Geordan G. Pursglove
- Employees
- 2
- Beta
- 0.84
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as (— ÷ $3.37) − 1 = — (DCF, example).